Rate and Predictors of Relapse in the Treatment of Hepatitis C in Real-Life Clinical Practice in Spanish Hospitals (FAST-4).
Phase of Trial: Phase IV
Latest Information Update: 05 Jul 2012
At a glance
- Drugs Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms FAST-4
- Sponsors Merck & Co; Schering-Plough
- 22 Apr 2012 Actual patient number changed from 278 to 279 as reported by ClinicalTrials.gov.
- 11 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jan 2011 Planned end date changed from 1 Jan 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.